The 4 most recent market catalysts affecting $MCRB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 75
Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine
Seres Therapeutics (MCRB) announced the publication of its SER-155 Phase 1b clinical trial results in Nature Medicine. This is a significant event as publication in a prestigious j…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 55
Seres Therapeutics To Present Preclinical Data Supporting Development Of SER-428, Investigational Oral Liquid LBP To Reduce Risk Of Bloodstream Infections In Critically Ill Patients, At IDWeek 2026
Seres Therapeutics (MCRB) is announcing an upcoming presentation of preclinical data for SER-428, an investigational oral liquid LBP. This matters because it highlights progress in…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 65
Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And Units
Seres Therapeutics has filed a universal shelf registration statement for up to $300 million in various securities. This is a common corporate finance move that provides the compan…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 95
Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate
Seres Therapeutics (MCRB) reported a substantial beat on both its Q2 EPS and sales estimates. The company posted a profit of $0.47 per share, a significant turnaround from an estim…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.